BiotechTube

ONO-4578 + Oxaliplatin + Capecitabine + S-1 + Nivolumab + Placebo

Phase 2Active
0 views this week 0 watching💤 Quiet
Interest: 39/100
39
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Gastric Cancer

Conditions

Gastric Cancer

Trial Timeline

Jan 10, 2024 → Jul 31, 2027

NCT ID
NCT06256328

About ONO-4578 + Oxaliplatin + Capecitabine + S-1 + Nivolumab + Placebo

ONO-4578 + Oxaliplatin + Capecitabine + S-1 + Nivolumab + Placebo is a phase 2 stage product being developed by Ono Pharmaceutical for Gastric Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT06256328. Target conditions include Gastric Cancer.

What happened to similar drugs?

5 of 20 similar drugs in Gastric Cancer were approved

Approved (5) Terminated (3) Active (13)
✅ApatinibTabletsJiangsu Hengrui MedicineApproved
✅ApatinibJiangsu Hengrui MedicineApproved
✅Esomeprazole SodiumAstraZenecaApproved
✅trastuzumab [Herceptin]RocheApproved
✅Methylnaltrexone only + Codeine only + Methylnaltrexone + codeine + Placebo + placeboPfizerApproved
🔄Trastuzumab + Fluorouracil + Cisplatin + CapecitabineChugai PharmaceuticalPhase 3
🔄Trastuzumab deruxtecan + Ramucirumab + PaclitaxelDaiichi SankyoPhase 3

Hype Score Breakdown

Clinical
12
Activity
12
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT06256328Phase 2Active

Competing Products

20 competing products in Gastric Cancer

See all competitors
ProductCompanyStageHype Score
pemetrexed + cisplatinEli LillyPhase 1/2
32
InfigratinibLianBioPhase 2
17
InfigratinibLianBioPhase 2
21
Ramucirumab + MEDI4736Eli LillyPhase 1
29
RamucirumabEli LillyPhase 2
35
Trastuzumab + Capecitabine + CisplatinCelltrionPhase 2
31
Trastuzumab + Fluorouracil + Cisplatin + CapecitabineChugai PharmaceuticalPhase 3
40
Fluorouracil (5-FU) + Capecitabine + Durvalumab + Oxaliplatin + Trastuzumab + Trastuzumab deruxtecan + Cisplatin + Pembrolizumab + Volrustomig + RilvegostomigDaiichi SankyoPhase 2
42
Trastuzumab DeruxtecanDaiichi SankyoPhase 2
35
Trastuzumab deruxtecan + Ramucirumab + PaclitaxelDaiichi SankyoPhase 3
44
Trastuzumab deruxtecanDaiichi SankyoPre-clinical
33
Trastuzumab Deruxtecan (T-DXd) monotherapy + T-DXd, Durvalumab and Capecitabine CombinationDaiichi SankyoPhase 2
42
Trastuzumab deruxtecan + BevacizumabDaiichi SankyoPhase 2
42
Trastuzumab deruxtecanDaiichi SankyoPhase 2
35
Trastuzumab deruxtecan (T-DXd)Daiichi SankyoPre-clinical
33
DS-8201aDaiichi SankyoPhase 1
29
Trastuzumab deruxtecanDaiichi SankyoPhase 2
39
Irinotecan + NimotuzumabDaiichi SankyoPhase 3
32
Trastuzumab Deruxtecan + pembrolizumab + Trastuzumab + ChemotherapyDaiichi SankyoPhase 3
47
Trastuzumab deruxtecan + 5FU/LV + Trastuzumab deruxtecan + FLODaiichi SankyoPhase 1/2
39